Mitochondrial & longevity research compounds
SR9009 (Stenabolic)
Also known as stenabolic · SR-9009
A synthetic ligand reported to activate REV-ERB circadian nuclear receptors — though later work showed REV-ERB-independent effects.
In 60 seconds
Preclinical research tool only; poor oral bioavailability is widely noted; sold illicitly as a performance compound. No human safety data.
- Showed SR9009 affects proliferation and metabolism independently of REV-ERB, questioning its specificity.
- In prostate-cancer models, SR9009 acted through LXRα/FOXM1 independently of REV-ERBs.
- SR9009 inhibited mast-cell activation independently of the circadian clock.
Mechanism
REV-ERBα/β link the circadian clock to metabolism. SR9009 was reported as a REV-ERB agonist that altered metabolism in mice; a 2019 study found it changes cell proliferation and metabolism even in cells lacking REV-ERB, questioning its specificity.
Research status
Preclinical research tool only; poor oral bioavailability is widely noted; sold illicitly as a performance compound.
Key studies
Showed SR9009 affects proliferation and metabolism independently of REV-ERB, questioning its specificity.
SR9009 has REV-ERB-independent effects on cell proliferation and metabolism — Proc Natl Acad Sci U S A, 2019 · PMID 31127047
In prostate-cancer models, SR9009 acted through LXRα/FOXM1 independently of REV-ERBs.
SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs — Cell Death Dis, 2022 · PMID 36357378
SR9009 inhibited mast-cell activation independently of the circadian clock.
The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock — Int J Mol Sci, 2019 · PMID 31847374
Safety signals in the literature
No human safety data.
Legal status (South Africa)
Research compounds; not registered medicines for human use in South Africa unless stated otherwise.
Related compounds we stock
Not stocked yet — get notified
Tell us you want SR9009 (Stenabolic) and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add SR9009 (Stenabolic)
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Questions
What is SR9009 (Stenabolic)?
A synthetic ligand reported to activate REV-ERB circadian nuclear receptors — though later work showed REV-ERB-independent effects. REV-ERBα/β link the circadian clock to metabolism. SR9009 was reported as a REV-ERB agonist that altered metabolism in mice; a 2019 study found it changes cell proliferation and metabolism even in cells lacking REV-ERB, questioning its specificity.
What is the research status of SR9009 (Stenabolic)?
Preclinical research tool only; poor oral bioavailability is widely noted; sold illicitly as a performance compound.
What safety signals are reported for SR9009 (Stenabolic)?
No human safety data.
Does Living Water Labs stock SR9009 (Stenabolic)?
Not at present. SR9009 (Stenabolic) is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Research compounds; not registered medicines for human use in South Africa unless stated otherwise.
More in Mitochondrial & longevity
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
